

NB-63-0003



NeoLux Viability assessment by loss of efflux protein function #Cat: NB-63-0003 Size:96Well

Description: Demonstration NeoLux Viability assessment by loss of efflux protein function, sufficient reagents for 1000determinations in 96-well plates

Updated: 03 April 2024

Kit content Neolux solution **(1 vial) For research only. Not for use in diagnostic procedures.**

Storage: 2-4°C, protect from light

Contents

Description	2
Mechanism	2
Supplied Materials	
Safety	. 3
Optimization protocol (to be carried out for the use of each new cell line)	
General Assay Protocol	. 4
Analysis	. 5
Example of Neolux Assay Results	6

Manufacturer's address: 74 rue des suisses 92000 Nanterre, France

Important Licensing Information: process covered by patents. By use of this kit, you accept the terms and conditions of all applicable Limited Use Label Licenses.




Description

The live cell Viability Assay kit is based on NeoLux technology that measures the state of homeostasis or cell damage by a fluorescence readout. The technology has been optimized for high throughput on 96- and 384-well plates, suitable for commercial fluorescence readers according to a very simple protocol limited to the addition of the Neolux solution in the culture medium and two fluorescent measurements.

- For 1000 measure points in 96-well plates
- One-step procedure
- No washes
- Storage 4°C
- Time to expiration: 6 months after receipt
- Standard procedure to most immortalized cell lines, primary cells, hiPSCs, ...
- Can be used on multiplexing

Mechanism

The process is called Neolux because the fluorescence level of the fluorescent biosensor increases during its photoinduction by illumination. The biosensor passively enters the cells but is quickly removed from functional cells by efflux transport proteins, resulting in a low fluorescent signal. When the light is applied, biosensor photoinduction generates intracellular ROSs, which alter the cell homeostasis or cell's ability to remove the biosensor, triggering its massive entry within the cells, and resulting in an increased fluorescence signal. If cells have been previously incubated with a toxic substance causing alteration of cellular functions, the biosensor enters massively, leading to a high fluorescence signal with consequently no increase after light application.





Supplied Materials

Name	Amount	Storage
Neolux solution	17,5µL	4°C for 6 months
		Protect from light

Each kit contains sufficient reagents to perform 1000 assays in 96-well plates.

Materials Required but Not Supplied

- •Cells on plate
- Appropriate cell culture medium*
- •96-well plate fluorescence reader
- •Neostress Illuminator if required

* We recommend the use of serum-free medium to avoid cells growing during the treatment with the toxic compound or condition


Safety 🔔

This product is for research purposes only and not for human or therapeutic use. Potentially harmful. Avoid prolonged or repeated exposure. Avoid getting in eyes, on skin, or on clothing. Wash thoroughly after handling. If eye or skin contact occurs, wash affected areas with plenty of water for 15 minutes and seek medical advice. In case of inhaling or swallowing, move individual to fresh air and seek medical advice immediately.

Optimization protocol (to be carried out for the use of each new cell line)


This protocol allows to find the optimized biosensor (Neolux Solution) incubation time before starting the illumination process. For this, 9 incubation times should be tested (10min, 20min, 30min, 40min, 50min, 60min, 70min, 80min and 90min).

Plate layout





Protocol



- 1. Remove culture medium from the wells (9 in triplicates), then add 100 μ L of culture medium
- 2. Prepare the biosensor solution: 1μ L of Solution A1 + 749 μ L of culture medium without serum. Mix with a pipette and keep the solution protected from light
- 3. Add 10µL of the diluted Neolux solution in column 2 wells (condition 90min)
- 4. Incubate 10min at room temperature in the dark
- 5. Add 10μ L of the diluted Neolux solution in column 3 wells (condition 80min)
- 6. Incubate 10min at room temperature in the dark
- 7. Repeat steps 5 and 6 every 10 minutes in the next columns until column 10
- 8. Follow step 4-6 of the General Assay Protocol.


Analysis

The post-illumination signal should be higher than the pre-illumination signal. Calculate the ratio:

$R=(F_{post}/F_{pre})*100$

The optimized profile condition is characterized by the highest ratio. Keep the set up for routine use.

General Assay Protocol



Cell treatment with sample should be realized in medium in a final volume of 100μ L/well.

1. For 96 wells, prepare 1.4µL of **Neolux solution** + 1048.6µL of culture medium. Mix with the pipette

2. Add 10µL of this diluted Neolux solution per well. Avoid exposing to excessive light during this step and next steps.

3. Incubate the plate at room temperature in the dark for the optimum time determined during the optimization phase

4. Read fluorescence (Fpre) at the following wavelengths:

 $\lambda_{\text{Excitation}}$ = 505nm (±10nm)

```
\lambda_{\text{Emission}}= 535nm (±10nm)
```

- 5. Illuminate the plate using the Neostress illuminator* with the "Neolux mode"
- 6. Wait 1 min and read fluorescence (Fpost)

Neo-Biotech 74 rue des Suisses – 92000 Nanterre - FRANCE



N.B.: Non-specific fluorescence can be measured by reading fluorescence before step 2.

* Alternatively, follow the instructions detailed in the Neolux application note provided by the fluorescence reader's Supplier

Analysis

In each well, the ratio R of fluorescence intensities measured before (Fpre) and after (Fpost) illumination is calculated as:

R= (F_{post}/F_{pre})*100

Acceptance criteria: ratio value of non-toxic control should be above 100 (usually 200 to 1000); ratio values for toxic conditions should tend to 100.

Example of NeoLUX Assay Results




Figure 1. Dose-response values of NeoLux Ratio obtained for hepatocytes (HepG2 cells) after 24h of treatment with a toxic compound (chloroquine).




Figure 2. Dose-response curve and EC50 (μ M) determination obtained after sigmoid fit by Graphpad Prism9 software.